01

2023

-

03

Committed to new drug research and development and medical high-tech development

Classification:

Company News


Shandong Yumankun Biotechnology Co., Ltd. was established in June 2018. It is a national high-tech enterprise, a provincial-level specialized and special new small and medium-sized enterprise, and has passed the ISO9001 quality management system certification.

company is committed to the research and development of new drugs and high-tech development of medicine. Since its establishment, it has completed more than 30 scientific and technological achievements transformation, and has many varieties of generic drugs covering high-tech barriers, second-class new drugs and a variety of improved and innovative drugs. Its varieties cover neurology, respiratory, nephrology, gastroenterology and other fields. With more than 3000 square meters of R & D center, it is expected that in the next 3 to 5 years, the company will build a pharmaceutical innovation base integrating R & D, investment and operation. In early 2021, the company signed a capital increase and share expansion cooperation agreement with Shandong Kangmeile Pharmaceutical Technology Co., Ltd., accounting for 60% of the shares. Shandong kangmeile pharmaceutical technology co., ltd. has a laboratory area of 3200 square meters. it is Jinan's 5150 talent enterprise, overseas student enterprise, national high-tech enterprise, specialized and special new enterprise. it is listed on the science and technology board of Qilu equity trading center (stock code 172007). it is ahead of the new drug research and development industry through ISO9001 quality system certification, intellectual property management system certification, and SOP management in the whole research and development process.

The company has a full service system from project research, synthesis process development, impurity preparation, preparation research, quality research, stability research, registration application to obtaining drug registration certificate and production technology guidance.

Values: Pragmatism, Innovation, Responsibility, Win-Win
Mission: Focus on pharmaceutical science and technology, seek health for the public
The mission of the company is the foundation of the company, which explains the value and significance of the company's existence; the company has always taken the drug research and development as the supporting force for the sustainable development of the enterprise, integrated the resources of the whole industrial chain in research and development, and cooperated with the pharmaceutical institutions of higher learning, the State Key Laboratory of Pharmaceuticals and other scientific research units to develop new products, and at the same time, also with a number of well-known pharmaceutical companies to establish a long-term cooperation between the industry, academia and research, so as to ensure that there is a sustained innovation and product listing. The company also has a strict product quality management and control system, product quality is the lifeblood of the company's survival and development, in order to ensure the efficacy and safety of the drug, our company has implemented a strict quality audit and assessment, and comprehensively improve the qualification rate of the products shipped.
Company vision: to become a leading scientific and technological innovation-oriented pharmaceutical enterprises
The company has always adhered to the scientific concept of development to lead the overall situation, product innovation as the driving force, the R & D center as a grip, sales as a leader, in the independent innovation capacity continues to increase, forming a benign pattern of "marketed generation, storage generation, R & D generation". In the future development, Yumankun will continue to "patient-centered, clinical value-oriented" as the goal, and at the same time innovative technology path and business model, driving the transformation and upgrading of product research and development, production technology and marketing model, to innovative, international pharmaceutical group steadily marching towards the development of China's pharmaceutical industry to make a new and greater contribution to the development of China!

Related News

Shandong Yumankun Biotechnology Co., Ltd. piracetam injection ninth batch of state procurement selected

2023-11-08

On November 6, the ninth batch of national drug centralized volume purchasing meeting was held in Shanghai. Shandong Yumangkun Biotechnology Co., Ltd. consistency evaluation over the evaluation of the product piracetam injection was selected.

Good News|Shandong Yumankun Biotechnology Co., Ltd. won the eighth batch of national centralized purchasing of pharmaceutical products.

2023-09-27

Good News|Shandong Yumankun Biotechnology Co., Ltd. won the eighth batch of national centralized purchasing of pharmaceutical products.

Circular of the National Medical Security Bureau on Further Deepening the Intelligent Audit and Monitoring of the Medical Security Fund

2023-09-09

Circular of the National Medical Security Bureau on Further Deepening the Intelligent Audit and Monitoring of the Medical Security Fund

Notice on the Filling of Information on Drugs Related to the Ninth Batch of Centralized Purchasing of Drugs by State Organizations

2023-08-30

Notice on the Filling of Information on Drugs Related to the Ninth Batch of Centralized Purchasing of Drugs by State Organizations

Online message